


# COURSE DESCRIPTION AND PROGRAM OBJECTIVES



Heart disease is the leading cause of death in women in the US and accounts for more deaths each year than all of the other causes combined. The rates of death are even higher in women of racial or ethnic minority. One in three women will die of some form of heart or vascular disease. However, only one-third of women are aware of this statistic and only half would call 911 if they had symptoms of a heart attack. Compared to men, women are less likely to receive standard of care of treatment for chest pain, less likely to be referred to a cardiologist, and less likely to be admitted to the hospital. It is our mission to educate healthcare providers about the impact of cardiovascular disease on women and empower them to be advocates for women's cardiovascular health.

This educational symposium will review the current epidemiology of cardiovascular disease in women, and examine women-specific cardiovascular issues related to diagnosis and treatment. Cardiovascular risk factors and diseases more common in women will be examined, including stress and ischemia without obstructive CAD. In addition, cardiac-specific risk stratification during reproductive years, an update on lipid therapies, and peripartum cardiomyopathy will be discussed. Sex specific differences in the management of congestive heart failure and cardiac arrhythmias will be reviewed with emphasis on sex-specific differences and considerations. State of the art therapies for deep vein thrombosis/pulmonary embolism, resistant hypertension and percutaneous treatments of valvular heart disease will be included, with an emphasis on gender-specific outcomes. This year will include a look into the current representation of women in the cardiovascular work-force and its implication on cardiovascular outcomes in women patients. Finally, case-based presentations will highlight ongoing dilemmas in cardiovascular management, and the use of novel pharmaceutical agents and invasive techniques.

The objective of this symposium is to educate healthcare providers on gender-specific approaches in prevention, diagnosis, and treatment of women with a broad range of cardiovascular diseases.

## OVERALL OBJECTIVES

1. Review and understand the current epidemiology of cardiovascular disease in women.
2. Educate the practitioner on the risk factors of cardiovascular disease more common in women that are oftentimes overlooked.
3. Review the current guidelines for the management of cardiovascular disease, congestive heart failure, atrial fibrillation, and peripheral vascular disease with an emphasis on sex-specific outcomes.

## ADDITIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to:

- Be aware of the current epidemiology of cardiovascular disease in women
- Review recent major cardiovascular trials and their therapeutic implications for women
- Review the sex differences in therapies of heart
- Discuss the implications of sex differences in therapies for heart failure on clinical outcomes in women
- Understand the role of GLP-1 agonists in the prevention and treatment of cardiovascular disease in women
- Understand the current nomenclature and epidemiology of microvascular disease
- Review the current treatment guidelines for microvascular disease
- Review the epidemiology of deep vein disease
- Discuss the best treatment modalities for deep vein disease for women
- Review the definition of resistant hypertension and drug therapies
- Explore novel invasive therapies for resistant hypertension
- Review the current statistics of valvular heart disease in women
- Discuss the preferred treatment of valvular heart disease for women
- Discuss the sex specific differences in therapies for cardiac arrhythmias
- Understand the importance of cardiovascular screening during reproductive years
- Discuss the implications of cardiovascular risk factors on pregnancy
- Discuss the current incidence and prevalence of peripartum cardiomyopathy
- Review the current acute and long term treatment and future implications of peripartum cardiomyopathy
- Review the newer cholesterol lowering agents, including mechanism of action and indications
- Discuss new risk tools and recommendations for therapy
- Discuss the under-representation of women providing cardiovascular care
- Explore the reasons for this disparity and ways to increase women in cardiology
- Use case-based presentations to review new therapeutic agents for various cardiovascular diseases

## 7TH ANNUAL SYMPOSIUM

# Contemporary Management of Cardiovascular Disease in Women

## NEEDS ASSESSMENT

Heart disease is the leading cause of death in women in the U.S. and accounts for more deaths each year than all of the other causes combined. In women of racial or ethnic minority the rates of death are even higher. One in three women will die of some form of heart or vascular disease. However, only one-third of women are aware of this statistic and only half would call 911 if they had symptoms of a heart attack. Compared to men, women are less likely to receive standard of care of treatment for chest pain, less likely to be referred to a cardiologist, and less likely to be admitted to the hospital. It is our mission to educate healthcare providers about the impact of cardiovascular disease on women and empower them to be advocates for women's cardiovascular health.

## TARGET AUDIENCE

This program has been designed to provide primary care physicians, internists, cardiologists, nurse practitioners, physician assistants, nurses, pharmacists and other healthcare providers with the necessary information to increase knowledge and awareness of cardiovascular disease in women with the goal of improving patient care.

## CULTURAL AND LINGUISTIC COMPETENCY AUDIENCE

This activity is in compliance with California Assembly Bill 1195 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables health care professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient's primary language. Cultural and linguistic competency was incorporated into the planning of this activity.

## FACULTY DISCLOSURE

It is our policy to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. All conflicts of interest will be resolved prior to an educational activity being delivered to learners through one of the following mechanisms 1) altering the financial relationship with the commercial interest, 2) altering the individual's control over CME content about the products or services of the commercial interest, and/or 3) validating the activity content through independent peer review. All persons are also required to disclose any discussions of off label/unapproved uses of drugs or devices. Persons who refuse or fail to disclose will be disqualified from participating in the CME activity.

## FURTHER INFORMATION

Complete Conference Management  
Phone: 619-299-6673 Fax: 619-299-6675  
Email: [info@cmmmeetings.com](mailto:info@cmmmeetings.com)

## 7TH ANNUAL SYMPOSIUM

# Contemporary Management of Cardiovascular Disease in Women



June 8, 2024

Millennium Biltmore Hotel

Los Angeles, California

COURSE DIRECTOR

Christina Economides, MD, MM, FSCAI

SUPPORTED BY



Good Samaritan  
Hospital

Endorsed by



WomensCVDLA.com

# FACULTY

## COURSE DIRECTOR



**Christina Economides, MD, MM, FSCAI\***  
 Director, STEMI Receiving Center  
 Director, Women's Cardiovascular Health Program  
 Director, Cardiac Rehabilitation Program  
 Director, Transradial Cardiac Catheterization Program  
 Associate Program Director, Harbor UCLA Medical Center/PIH Health Good Samaritan Hospital  
 Interventional Cardiology Fellowship Program  
 PIH Health Good Samaritan Hospital  
 Los Angeles, CA

## GUEST FACULTY



**Ulrika Birgersdotter-Green, MD**  
 Director, Pacemaker and ICD Services  
 Professor of Medicine  
 UC San Diego Health  
 La Jolla, CA



**Margo B. Minissian, PhD, ACNP, FAHA, AACC**  
 Executive Director, Geri and Richard Brawer Nursing Institute  
 Simms/Mann Family Foundation  
 Endowed Chair in Nurse Education, Innovation and Research  
 Assistant Professor, Cardiology  
 Director, Postpartum Heart Health Program  
 Cedars-Sinai Medical Center  
 Los Angeles, CA



**Steven Burstein, MD, FACC\***  
 Director, Interventional Cardiology  
 Director, Structural Heart Program  
 PIH Health Good Samaritan Hospital  
 Los Angeles, CA



**Priya Pillutla, MD, FACC**  
 Associate Clinical Professor  
 David Geffen School of Medicine at UCLA  
 Harbor-UCLA Medical Center  
 Torrance, CA




**Uri Elkayam, MD, FACC**  
 Professor of Medicine,  
 Division of Cardiology  
 University of Southern California  
 Keck School of Medicine  
 Los Angeles, CA



**Karol Watson, MD, PhD, FACC**  
 Professor of Medicine/Cardiology  
 Co-director, UCLA Program in Preventive Cardiology  
 Director, UCLA Barbra Streisand Women's Heart Health Program  
 David Geffen School of Medicine at UCLA  
 Los Angeles, CA  
 John Mazziotta, MD, PhD Term Chair in Medicine  
 Los Angeles, CA



**Michelle Kittleson, MD, PhD, FACC**  
 Professor of Medicine  
 Director of Post Graduate Medical Education in Heart Failure and Transplantation  
 Director of Heart Failure Research  
 Cedars Sinai Medical Center  
 Los Angeles, CA



**Janet Wei, MD, FACC**  
 Assistant Professor, Cedars-Sinai Smidt Heart Institute  
 Associate Director, Cedars-Sinai Cardiology Fellowship Training Program  
 Associate Medical Director, Biomedical Imaging Research Institute  
 Co-Director, Stress Echocardiography, Noninvasive Cardiac Laboratory  
 Barbra Streisand Women's Heart Center  
 Los Angeles, CA



**Guy Mayeda, MD, FACC, FSCAI\***  
 Chief, Vascular Disease Program  
 PIH Health Physicians  
 President, Los Angeles Cardiology Associates  
 Los Angeles, CA



**Katrine Zhiroff, MD, FACC, FSCAI\***  
 Interventional Cardiologist  
 Director, Cardiology Services  
 PIH Health Downey Hospital  
 Downey, CA

\*Los Angeles Cardiology Associates

# PROGRAM - Saturday, June 8, 2024

## MORNING SESSION

7:00

*Registration Opens*

7:30-8:30am

*Breakfast Served*

7:30-8:30am

**Product Theatre (Non-CME)**

Title TBA

8:40-8:45

**Welcome and Introductory Remarks**

Christina Economides, MD, MM, FSCAI

8:45-9:05

**Cardiovascular Disease in Women: 2024 Update**

Christina Economides, MD, MM, FSCAI

9:05-9:25

**Sex Differences in Therapies and Outcomes of Heart Failure in Women**

Michelle Kittleson, MD, PhD, FACC

9:25-9:45

**Glucagon-Like Peptide 1 (GLP-1) Agonists for Prevention and Treatment of Cardiovascular Disease in Women**

Karol Watson, MD, PhD, FACC

9:45-10:05

**Evaluation and Therapies for Coronary Microvascular Disease**

Janet Wei, MD, FACC

10:05-10:20

**Question & Answer**

10:20-10:35

*Break / Visit Exhibits*

10:35-10:55

**Sex Differences in Deep Vein Thrombosis, Pulmonary Embolism and May-Thurner Syndrome**

Guy Mayeda, MD, FACC

10:55-11:15

**Treatment of Resistant Hypertension and Role of Novel Device Therapies**

Katrine Zhiroff, MD, FACC, FSCAI

11:15-11:35

**Sex Differences in the Percutaneous Treatments of Valvular Heart Disease**

Steven Burstein, MD, FACC

11:35-11:55

**Sex Differences in Drug and Device Therapy in Cardiac Arrhythmias**

Ulrika Birgersdotter-Green, MD

11:55-12:10

**Question & Answer**

12:20-1:20

**Lunch - Product Theatre I (Non-CME)**

**hATTR Progression: Addressing Polyneuropathy**

*Speaker:* Richard Wright, MD

*Supported by:* AstraZeneca

## AFTERNOON SESSION

1:30-1:50

**Cardiovascular Disease Risk During Reproductive Years: Assessment and Management**

Priya Pillutla, MD, FACC

1:50-2:10

**Peripartum Cardiomyopathy: Current State of Knowledge, Treatment and Implications**

Uri Elkayam, MD, FACC

2:10-2:30

**Novel Cholesterol Lowering Agents and Guideline Recommendations**

Margo B. Minissian, PhD, ACNP, FAHA, AACC

2:30-2:45

**Question & Answer**

2:45-3:00

*Break / Visit Exhibits*

3:00-3:20

**Increasing Gender Representation in the Cardiovascular Work-Force**

Christina Economides, MD, MM, FSCAI

Katrine Zhiroff, MD, FACC, FSCAI

Steven Burstein, MD, FACC

3:20-3:40

**Clinical Vignettes: New Therapeutic Agents**

- Hypertrophic Obstructive Cardiomyopathy (HOCM)
- Pulmonary Arterial Hypertension (PAH)
- Update on Amyloidosis in Female Patients

Symposia Faculty

*Moderators:* Christina Economides, MD, MM, FSCAI

Katrine Zhiroff, MD, FACC, FSCAI

3:40-4:40

**Trial Updates Using Case-Based Presentations:**

- Sex Differences in Heart Failure Following Acute Coronary Syndromes
- Long-term Clinical Outcomes in Women Treated with Barostim for Heart Failure with Reduced Ejection Fraction (HFrEF)
- Update on EMPOWER Trial: IVL for Calcified CAD in Women
- Update on Therapy for Recurrent Pericarditis
- Outcomes of Cardiogenic Shock and PCI in Women Treated with Mechanical Circulatory Support

*Moderators:* Christina Economides, MD, MM, FSCAI

Katrine Zhiroff, MD, FACC, FSCAI

4:40-5:00

**Question & Answer**

5:00-5:05

**Closing Remarks**

5:05

**Adjourn**

# COURSE INFORMATION

## ACCREDITATION

The AAFP has reviewed 7th Annual Symposium Contemporary Management of Cardiovascular Disease in Women and deemed it acceptable for up to **6.50** Live AAFP Prescribed credit(s). Term of Approval is from 06/08/2024 to 06/08/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to *AMA PRA Category 1 credit(s)*<sup>TM</sup> toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

## REGISTRATION FEES

	on or before May 8, 2024	on or after May 9, 2024
Physician Registration	\$150	\$175
Nurse / Allied Health	\$100	\$125
Physician in Training	No Charge (Please present a letter of verification upon check-in)	No Charge

**Register Online at: [WomensCVDLA.com](http://WomensCVDLA.com)**

## LOCATION

**Millennium Biltmore Hotel**  
 506 S. Grand Avenue  
 Los Angeles, California 90071  
 Phone: 213-624-1011  
[www.millenniumhotels.com](http://www.millenniumhotels.com)



The Millennium Biltmore Hotel has been the premier choice for celebrities, presidents and dignitaries for nearly 90 years. Few Los Angeles hotels boast the ideal locale and sumptuous comforts this luxury hotel has to offer. Situated at the heart of L.A.'s vibrant cultural district, the hotel is just steps away from major attractions, such as Walt Disney Concert Hall and Dodger Stadium.

**\$170.00 - Special Group Rate Available (Deadline: May 28, 2024):**

A limited number of guest rooms are available for a rate of \$170 Single/Double, plus tax and parking. Reservations must be guaranteed by a major credit card. Cancellations without penalty must be made 36 hours prior to your arrival.

**To receive the symposium discount please contact:**

Jessica Medina  
 213-612-1502

## FURTHER INFORMATION

Complete Conference Management  
 3320 Third Avenue, Suite C  
 San Diego, CA 92103

Phone: 619-299-6673

Fax: 619-299-6675

Email: [info@ccmmeetings.com](mailto:info@ccmmeetings.com)

## CANCELLATION POLICY

If your registration must be cancelled and a refund of your fee is desired, your fee, less \$25 for administrative costs, will be refunded upon receipt of a written request that includes your signature. No refunds will be made after **May 18, 2024**. Please allow up to 6 weeks for a refund.